Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Frontiers in Immunology
|
November 12, 2020
Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
Joshua R D Pearson, Stefania Cuzzubbo, Simon McArthur, et al.
Journal for Immunotherapy of Cancer
|
August 5, 2020
Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients
Stefania Cuzzubbo, Pauline Tetu, Sarah Guegan, et al.
Neurology
|
July 19, 2022
Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Renata Ursu, Didier Maillet, Catherine Belin, et al.
European Journal of Neurology
|
June 21, 2025
Baseline Cognitive and Neurological Status Does Not Modify the Occurrence of ICANS in CAR T-Cell Therapy for Aggressive B-Cell Lymphoma
Renata Ursu, Claudia Barsan, Roberta Di Blasi, et al.
Cancers
|
September 19, 2020
Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases
Pauline Tétu, Lila Sirven-Villaros, Stefania Cuzzubbo, et al.
Expert Review of Anticancer Therapy
|
December 22, 2018
Management of immune-related adverse events resulting from immune checkpoint blockade
Barouyr Baroudjian, Dimitri Arangalage, Stefania Cuzzubbo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 27, 2024
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas
Alberto Picca, Mehdi Touat, Lisa Belin, et al.
Scientific Reports
|
July 1, 2026
Long-term treatment outcomes of immune checkpoint inhibitor-related neuropathies: a French multicenter cohort study
Stefania Cuzzubbo, Edouard Berling, Pierre Lozeron, et al.
Oncoimmunology
|
April 11, 2018
Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8<sup>+</sup> T cell activation in the presence of adjuvant temozolomide
Serena Pellegatta, Marica Eoli, Valeria Cuccarini, et al.
Journal of Neuro-Oncology
|
December 10, 2014
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab
Anna Luisa Di Stefano, Marianne Labussiere, Giuseppe Lombardi, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Frontiers in Immunology
|
November 12, 2020
Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
Joshua R D Pearson, Stefania Cuzzubbo, Simon McArthur, et al.
Journal for Immunotherapy of Cancer
|
August 5, 2020
Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients
Stefania Cuzzubbo, Pauline Tetu, Sarah Guegan, et al.
Neurology
|
July 19, 2022
Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Renata Ursu, Didier Maillet, Catherine Belin, et al.
European Journal of Neurology
|
June 21, 2025
Baseline Cognitive and Neurological Status Does Not Modify the Occurrence of ICANS in CAR T-Cell Therapy for Aggressive B-Cell Lymphoma
Renata Ursu, Claudia Barsan, Roberta Di Blasi, et al.
Cancers
|
September 19, 2020
Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases
Pauline Tétu, Lila Sirven-Villaros, Stefania Cuzzubbo, et al.
Expert Review of Anticancer Therapy
|
December 22, 2018
Management of immune-related adverse events resulting from immune checkpoint blockade
Barouyr Baroudjian, Dimitri Arangalage, Stefania Cuzzubbo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 27, 2024
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas
Alberto Picca, Mehdi Touat, Lisa Belin, et al.
Scientific Reports
|
July 1, 2026
Long-term treatment outcomes of immune checkpoint inhibitor-related neuropathies: a French multicenter cohort study
Stefania Cuzzubbo, Edouard Berling, Pierre Lozeron, et al.
Oncoimmunology
|
April 11, 2018
Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8<sup>+</sup> T cell activation in the presence of adjuvant temozolomide
Serena Pellegatta, Marica Eoli, Valeria Cuccarini, et al.
Journal of Neuro-Oncology
|
December 10, 2014
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab
Anna Luisa Di Stefano, Marianne Labussiere, Giuseppe Lombardi, et al.
Page
of 3